Teva Pharmaceutical Industries (NYSE:TEVA) received a $11.00 target price from analysts at Royal Bank of Canada in a research report issued to clients and investors on Wednesday, November 29th. The firm presently has a “sell” rating on the stock. Royal Bank of Canada’s price objective points to a potential downside of 40.89% from the stock’s current price.
TEVA has been the subject of a number of other reports. Credit Suisse Group restated an “underperform” rating and issued a $8.00 target price (down from $14.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, November 6th. Wells Fargo & Company reiterated a “market perform” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, October 5th. Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Sunday, November 12th. BTIG Research set a $16.00 price objective on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research note on Tuesday, November 28th. Finally, Maxim Group reiterated a “hold” rating and set a $15.50 price objective on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 14th. Five investment analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries currently has an average rating of “Hold” and a consensus price target of $20.57.
Teva Pharmaceutical Industries (NYSE TEVA) opened at $18.61 on Wednesday. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The company has a market capitalization of $19,650.00, a price-to-earnings ratio of 3.63 and a beta of 0.55. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $38.31.
Institutional investors have recently bought and sold shares of the stock. San Francisco Sentry Investment Group CA bought a new position in Teva Pharmaceutical Industries in the second quarter valued at about $106,000. Kistler tiffany & co shop Companies LLC boosted its holdings in Teva Pharmaceutical Industries by 74.7% in the second quarter. Kistler tiffany & co shop Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after acquiring an additional 1,571 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its holdings in Teva Pharmaceutical Industries by 2.6% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after acquiring an additional 94 shares during the last quarter. Shelter Mutual Insurance Co bought a new position in Teva Pharmaceutical Industries during the second quarter worth about $133,000. Finally, Fayez Sarofim & Co. bought a new position in Teva Pharmaceutical Industries during the second quarter worth about $204,000. Institutional investors and hedge funds own 52.05% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/12/16/teva-pharmaceutical-industries-teva-pt-set-at-11-00-by-royal-bank-of-canada.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Thank you for taking the time to read this article. I hope you like it